Generex Biotechnology Value Stock - Dividend - Research Selection
Market price: 0,28 USD
Generex Biotechnology Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-6.121.260|
|Free cash flow||-6.125.876|
|Liabilities & Shareholders equity||45.382.900|
|Diluted shares outstanding||74.417.600|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||22.325.280,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2020-02-25,7.000000/5.000000; 2020-01-13,7.000000/5.000000; 2020-01-06,140.000000/100.000000; 2019-12-02,2.000000/1.000000; 2019-10-31,2.000000/1.000000; 2019-10-30,2.000000/1.000000; 2019-07-23,2.000000/1.000000; 2018-12-04,21.0000/1.0000; 2018-12-03,1.0000/21.0000; 2017-03-14,1.0000/1000.0000|
Description of the company
Generex Biotechnology Corporation is engaged in pharmaceutical and biotechnological research and development of drug delivery systems and technologies, and other activities. The Company offers a platform technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. It develops drug delivery systems and technologies for metabolic and immunological diseases. The Company is conducting pre-clinical and human clinical trials using its technology platforms in the areas of diabetes, pain management and cancers. Its buccal insulin product, Generex Oral-lyn, provides a needle-free means of delivering insulin for the patients suffering from type I diabetes and type II diabetes. Its buccal delivery technology involves the preparation of formulations in which an active pharmaceutical agent is placed in a solution with a combination of absorption enhancers and other excipients.